Close Menu

NEW YORK (360Dx) – Ortho Clinical Diagnostics and Beijing Leadman Biochemistry have collaborated to launch four assays for the Chinese market today.

The assays are cystatin C for the early diagnosis of chronic kidney disease; α-hydroxybutyrate dehydrogenase for the diagnosis of a heart attack; homocysteine for assessing risk factors for coronary atherosclerosis, Alzheimer's disease, venous embolism, neonatal defects, and habitual abortion; and total bile acids for the early detection of liver injury.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.